Ceftizoxime Dosing for Soft Tissue Infections
For soft tissue infections, ceftizoxime is dosed at 1-2 grams IV every 8-12 hours for moderate infections, or 2 grams IV every 8 hours for severe/refractory infections, with mandatory renal dose adjustments based on creatinine clearance. 1
Standard Dosing Regimen
According to FDA labeling, the dosing for soft tissue infections ("Other Sites") is 1:
- Moderate infections: 2-3 grams daily (1 gram IV every 8-12 hours)
- Severe or refractory infections: 3-6 grams daily (1 gram every 8 hours OR 2 grams every 8-12 hours)
- Life-threatening infections: 9-12 grams daily (3-4 grams every 8 hours)
The IV route is preferred for severe infections, bacterial septicemia, or localized abscesses.
Renal Dose Adjustments (Critical)
Dose modification is mandatory in renal impairment. After an initial loading dose of 500 mg-1 gram, adjust maintenance dosing as follows 1:
| Creatinine Clearance | Renal Function | Less Severe Infections | Life-Threatening Infections |
|---|---|---|---|
| 79-50 mL/min | Mild impairment | 500 mg q8h | 0.75-1.5 grams q8h |
| 49-5 mL/min | Moderate-severe | 250-500 mg q12h | 0.5-1 gram q12h |
| <5 mL/min (dialysis) | Dialysis patients | 500 mg q48h or 250 mg q24h | 0.5-1 gram q48h or 0.5 gram q24h |
Important caveat: For hemodialysis patients, time the dose to be given at the end of dialysis—no additional supplemental dosing is required 1. Research supports that these adjustments achieve similar minimum plasma concentrations across renal function groups while maintaining adequate time above MIC 2.
When to Add Anti-MRSA Coverage
Ceftizoxime lacks MRSA activity—you must add vancomycin 15 mg/kg IV every 12 hours if MRSA is suspected or confirmed. 3
The 2014 IDSA guidelines are explicit about this: for necrotizing or severe soft tissue infections where etiology may be polymicrobial or include community-acquired MRSA, empiric therapy should be broad 3. Ceftizoxime alone is insufficient for:
- Necrotizing fasciitis (especially post-varicella or minor trauma cases that may harbor MRSA)
- Diabetic foot infections with high MRSA prevalence
- Injection drug use-associated infections
- Any severe infection with systemic toxicity where MRSA cannot be excluded
Clinical pearl: Staphylococcus aureus requires 3-8 mcg/mL for inhibition, but methicillin-resistant strains are completely resistant to ceftizoxime 4.
When to Add Anaerobic Coverage
Add metronidazole 500 mg IV every 6-8 hours for polymicrobial infections involving anaerobes, particularly in these settings 3:
- Perianal abscesses or penetrating abdominal trauma
- Decubitus ulcers
- Injection drug use sites
- Infections spreading from genital sites (Bartholin abscess, episiotomy wounds)
- Axilla or perineum surgical site infections
The IDSA guidelines emphasize that polymicrobial necrotizing infections average 5 pathogens per wound, commonly including Bacteroides fragilis (which requires 16-64 mcg/mL for inhibition—above reliable ceftizoxime levels) 3, 4.
Pediatric Dosing
For children ≥6 months: 50 mg/kg IV every 6-8 hours, up to 200 mg/kg/day total (not exceeding adult maximum dose for serious infections) 1.
Critical Limitations
Ceftizoxime has NO activity against:
- Chlamydia trachomatis (add appropriate coverage for PID) 1
- MRSA (add vancomycin or alternative)
- Many anaerobes at therapeutic concentrations (add metronidazole)
- Enterococcus faecalis 4
Pseudomonas aeruginosa: Only moderately susceptible—use higher dosing and institute alternative therapy if response is not prompt 1.
Practical Algorithm
- Assess infection severity: Moderate vs severe/life-threatening
- Check renal function: Calculate CrCl and adjust dose accordingly
- Evaluate MRSA risk: Add vancomycin for necrotizing infections, diabetic wounds, IVDU, or systemic toxicity
- Assess anaerobic involvement: Add metronidazole for perianal, decubitus, genital source, or polymicrobial presentation
- Monitor response: If no improvement in 48-72 hours with Pseudomonas, switch agents
The half-life of 1.6-1.9 hours in normal individuals extends significantly in renal failure, making dose adjustments essential to avoid toxicity while maintaining efficacy 4.